Related Experiment Videos
Workshop II: "neuroprotection"--the Lugano consensus
P Riederer1, T Brücke, C Buhmann
1Clinical Neurochemistry, Clinic and Policlinic of Psychiatry and Psychotherapy, University of Würzburg, Germany.
Journal of Neurology
|February 24, 2001
Summary
Preclinical studies show strong neuroprotection evidence, but clinical proof is limited. Early Parkinson's disease treatment with drugs like ropinirole may offer neuroprotection, but late-stage intervention does not.
Area of Science:
- Neuroscience
- Clinical Pharmacology
- Neurology
Background:
- Overwhelming preclinical evidence supports neuroprotection.
- Clinical evidence for neuroprotection and neurorescue remains limited.
- Parkinson's disease (PD) research focuses on disease-modifying strategies.
Framework:
- Investigating neuroprotective agents in early Parkinson's disease.
- Utilizing Positron Emission Tomography (PET) for treatment monitoring.
- Evaluating the impact of treatment initiation timing on neuroprotection.
Implementation:
- Clinical trials with drugs like selegiline, amantadine, and dopamine agonists highlight the need for early intervention.
- A PET-controlled trial with ropinirole suggests efficacy in early PD.
- Late-stage initiation of neuroprotective strategies shows no benefit.
Implications:
- Early intervention is critical for potential neuroprotection in Parkinson's disease.
- Current therapeutic strategies may not achieve long-term neuroprotection.
- Further research is needed to overcome challenges in demonstrating clinical neuroprotection.